(S (NP (NP (DT The) (NN study)) (PP (IN of) (NP (JJ high-throughput) (JJ genomic) (NNS profiles))) (PP (IN from) (NP (DT a) (NNS pharmacogenomics) (NN viewpoint)))) (VP (VBZ has) (VP (VBN provided) (NP (NP (JJ unprecedented) (NNS insights)) (PP (IN into) (NP (NP (DT the) (JJ oncogenic) (NNS features)) (VP (VBG modulating) (NP (NN drug) (NN response)))))))) (. .))
(S (NP (NP (DT A) (JJ recent) (NN screening)) (PP (IN of) (NP (NN ~1,000) (NN cancer) (NN cell) (NNS lines))) (PP (TO to) (NP (NP (DT a) (NN collection)) (PP (IN of) (NP (JJ anti-cancer) (NNS drugs)))))) (VP (VBD illuminated) (NP (NP (DT the) (NN link)) (PP (IN between) (NP (NP (NNS genotypes)) (CC and) (NP (NN vulnerability)))))) (. .))
(S (ADVP (RB However)) (, ,) (PP (JJ due) (TO to) (NP (NP (JJ essential) (NNS differences)) (PP (IN between) (NP (NP (NN cell) (NNS lines)) (CC and) (NP (NNS tumors)))))) (, ,) (NP (NP (DT the) (NN translation)) (PP (IN into) (S (VP (VBG predicting) (NP (NN drug) (NN response)) (PP (IN in) (NP (NNS tumors))))))) (VP (VBZ remains) (ADJP (VBG challenging))) (. .))
(S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD proposed) (NP (NP (DT a) (NNP DNN) (NN model)) (SBAR (S (VP (TO to) (VP (VB predict) (NP (NN drug) (NN response)) (PP (VBN based) (PP (IN on) (NP (NP (NN mutation) (CC and) (NN expression) (NNS profiles)) (PP (IN of) (NP (NP (DT a) (NN cancer) (NN cell)) (CC or) (NP (DT a) (NN tumor))))))))))))) (. .))
(S (NP (DT The) (NN model)) (VP (VBZ contains) (NP (NP (NP (NP (DT a) (NN mutation)) (CC and) (NP (DT an) (NN expression) (NNS encoders))) (VP (JJ pre-trained) (S (VP (VBG using) (NP (DT a) (JJ large) (JJ pan-cancer) (NN dataset)) (S (VP (TO to) (VP (VB abstract) (NP (NP (NN core) (NNS representations)) (PP (IN of) (NP (NN high-dimension) (NNS data))))))))))) (, ,) (VP (VBN followed) (PP (IN by) (NP (DT a) (NN drug) (NN response) (NN predictor) (NN network)))))) (. .))
(S (PP (VBN Given) (NP (NP (DT a) (NN pair)) (PP (IN of) (NP (NN mutation) (CC and) (NN expression) (NNS profiles))))) (, ,) (NP (DT the) (NN model)) (VP (VBZ predicts) (NP (NP (NNP IC50) (NNS values)) (PP (IN of) (NP (CD 265) (NNS drugs))))) (. .))
(S (NP (PRP We)) (VP (VP (VBD trained) (CC and) (VBD tested) (NP (DT the) (NN model)) (PP (IN on) (NP (NP (DT a) (NN dataset)) (PP (IN of) (NP (CD 622) (NN cancer) (NN cell) (NNS lines)))))) (CC and) (VP (VBD achieved) (NP (NP (DT an) (JJ overall) (NN prediction) (NN performance)) (PP (IN of) (NP (NN mean) (VBN squared) (NN error))) (PP (IN at) (NP (NP (CD 1.96)) (PRN (-LRB- -LRB-) (NP (JJ log-scale) (NNP IC50) (NNS values)) (-RRB- -RRB-))))))) (. .))
(S (NP (DT The) (NN performance)) (VP (VBD was) (ADJP (JJ superior) (PP (IN in) (NP (NP (NN prediction) (NN error)) (CC or) (NP (NN stability)))) (PP (IN than) (NP (NP (CD two) (JJ classical) (NNS methods)) (CC and) (NP (NP (CD four) (NN analog) (NNP DNNs)) (PP (IN of) (NP (PRP$ our) (NN model)))))))) (. .))
(S (NP (PRP We)) (ADVP (RB then)) (VP (VBD applied) (NP (DT the) (NN model)) (S (VP (TO to) (VP (VB predict) (NP (NP (NN drug) (NN response)) (PP (IN of) (NP (NP (CD 9,059) (NNS tumors)) (PP (IN of) (NP (CD 33) (NN cancer) (NNS types)))))))))) (. .))
(S (NP (DT The) (NN model)) (VP (VBD predicted) (NP (DT both) (NP (VBN known)) (, ,) (PP (VBG including) (NP (NP (NP (NNP EGFR) (NNS inhibitors)) (PP (IN in) (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)))) (CC and) (NP (NP (NN tamoxifen)) (PP (IN in) (NP (NNP ER+) (NN breast) (NN cancer)))))) (, ,) (CC and) (NP (JJ novel) (NN drug) (NNS targets)))) (. .))
(S (NP (DT The) (JJ comprehensive) (NN analysis)) (VP (ADVP (RBR further)) (VBD revealed) (NP (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBG underlying) (NP (NP (DT the) (NN resistance)) (PP (TO to) (NP (DT a) (JJ chemotherapeutic) (NN drug) (NN docetaxel))) (PP (IN in) (NP (DT a) (JJ pan-cancer) (NN setting)))))) (CC and) (NP (NP (DT the) (JJ anti-cancer) (NN potential)) (PP (IN of) (NP (NP (DT a) (JJ novel) (NN agent)) (, ,) (NP (NNP CX-5461)) (, ,))) (PP (IN in) (S (VP (VBG treating) (NP (NP (NN gliomas)) (CC and) (NP (JJ hematopoietic) (NNS malignancies))))))))) (. .))
(S (ADVP (JJ Overall)) (, ,) (NP (PRP$ our) (NN model) (CC and) (NNS findings)) (VP (VBP improve) (NP (NP (NP (DT the) (NN prediction)) (PP (IN of) (NP (NN drug) (NN response)))) (CC and) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (JJ novel) (JJ therapeutic) (NNS options)))))) (. .))
